Showing 15 posts of 16 posts found.

FDA approves new medicines to treat paediatric type 2 diabetes

June 22, 2023
Medical Communications Diabetes, FDA, Synjardy, jardiance, paediatrics, type 2 diabetes

The US Food and Drug Administration (FDA) has announced that it has approved Jardiance (empagliflozin) and Synjardy (empagliflozin and metformin …


Lilly and Boehringer’s Jardiance reduces hospitalisation and CV death risk from heart failure at Phase 3

July 30, 2020
Research and Development Boehringer, Eli Lilly, jardiance, pharma

Boehringer Ingelheim and Eli Lilly have announced strong Phase 3 news on their sodium-glucose co-transporter-2 (SGLT2) inhibitor Jardiance (empagliflozin) in …


FDA turns down label expansion for Jardiance as an adjunct to insulin in type 1 diabetes

March 23, 2020
Sales and Marketing FDA, diabetes, jardiance, pharma

The FDA has chosen not to approve an expanded indication of 2.5mg Jardiance (empaglifozin) as an adjunct to insulin in …


FDA advisory committee votes down approval of Boehringer and Lilly’s drug for type 1 diabetes

November 14, 2019
Sales and Marketing Boehringer Ingelheim, Eli Lilly, empagliflozin, jardiance, pharma

Boehringer Ingelheim and Eli Lilly’s have been dealt a blow from the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC), …

FDA approves another indication for Lilly/Boehringer diabetes treatment

December 5, 2016
Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

Jardiance (empagliflozin), an oral SGLT02 inhibitor developed by Eli Lilly and distributed by Boehringer Ingelheim, has been approved by the …


Eli Lilly says FDA panel backs approval of Jardiance for cardiovascular indication

June 30, 2016
Research and Development, Sales and Marketing Eli Lilly, cardiovascular, diabetes, jardiance

US drugmaker Eli Lilly (NYSE: LLY) said a US regulatory panel has backed its Jardiance (empagliflozin) for reducing cardiovascular death …


Lilly and Boehringer Ingelheim to evaluate diabetes drug for treatment of heart failure

April 20, 2016
Research and Development Boehringer Ingelheim, Eli Lilly, cardiovascular death, diabetes, heart attack, jardiance, lilly

Eli Lilly (NYSE: LLY) and Boehringer Ingelheim have announced plans to conduct two outcome trials evaluating diabetes medicine Jardiance (empagliflozin) …


FDA reviews Jardiance as cardiovascular diabetes treatment

January 27, 2016
Research and Development, Sales and Marketing Boehringer Ingelheim, Eli Lilly, FDA, jardiance

The FDA has accepted Boehringer Ingelheim and Eli Lilly’s supplemental New Drug Application for their diabetes drug Jardiance to be …

Janssen Velcade

NICE recommends Velcade for MCL, and three diabetes drugs

December 23, 2015
Sales and Marketing Forxiga, NICE, Velcade, invokana, jardiance, mantel cell lymphoma, mcl

NICE has published final guidance recommending Velcade (bortezomib) as a treatment for previously untreated mantle cell lymphoma (MCL).  In the …

Jardiance scores more cardiovascular outcomes data

November 10, 2015
Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes

A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …


More positive CV data for Boehringer and Lilly’s Jardiance

September 21, 2015
Research and Development, Sales and Marketing Boehringer Ingelheim, EASD, Eli Lilly, cardiovascular risk, empagliflozin, jardiance, mortality risk, type 2 diabetes

Jardiance, an anti-diabetes drug produced by Boehringer Ingelheim and Eli Lilly, reduces the risk of death in people with type …

Boehringer assures future growth following sales drop

April 23, 2015
Sales and Marketing Boehringer, COPD, Glyxambi, Striverdi Respimat, empagliflozin, empagliflozin/linagliptin, financials, full year, jardiance, nintedanib, ofev, olodaterol, results

Boehringer says it is positioned for future growth in the wake of filing a decline in profit for 2014 and …

EMA image

EMA committee recommends five drugs for approval

March 30, 2015
Sales and Marketing Boehringer, CHMP, EMA, Eisai, Europe, Gardasil, Lenvima, Merck, akynzio, jardiance, lilly

Cancer and diabetes treatments are among those given the go ahead in the latest round of approvals by the EMA. …

NICE image

NICE decisions made on Bayer, Celgene and Boehringer drugs

March 26, 2015
Sales and Marketing Bayer, Boehringer, Celgene, NHS, Xarelto, imnovid, jardiance

In final guidance NICE has recommended Bayer’s Xarelto and Boehringer’s Jardiance for NHS funding, but not Celgene’s Imnovid. Bayer’s Xarelto …

Glyxambi image

Boehringer and Lilly score FDA yes for Glyxambi

February 3, 2015
Sales and Marketing Boehringer, FDA, Glyxambi, Tradjenta, empagliflozin, jardiance, lilly, linagliptin

The FDA has approved Glyxambi (empagliflozin/linagliptin), which has become the first combination of two diabetes drugs in their different classes …

Latest content